Previous studies in our laboratory have demonstrated that inhibitors of the PI3K/AKT/mTOR pathway have selective activity in ER+ breast cancer cell lines carrying activating mutations in PIK3CA [19, 20]. Here, AKT1 is linked to breast carcinoma.